New immune therapy tested for aggressive brain cancer recurrence
Disease control
Recruiting now
This early-stage study is testing the safety and best dose of an experimental drug called CUE-102 in adults whose glioblastoma brain cancer has returned for the first time. CUE-102 is designed to activate the body's immune system to fight the tumor. The study will enroll about 18…
Phase: PHASE1 • Sponsor: David Reardon, MD • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC